ArticleHereditas2025
METTL3 mediates m6A methylation of LCN2 through IGF2BP3 to promote ferroptosis in chronic obstructive pulmonary disease.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by persistent airflow obstruction. Studies have shown that Lipocalin 2 (LCN2) and Methyltransferase-like protein 3 (METTL3) are involved in COPD progression. However, whether LCN2 and METTL3 jointly regulate the progression of COPD and the molecular mechanism are still unclear.
methodsHuman lung microvascular endothelial cells (HMVECs) were treated with Cigarette smoke extract (CSE) to construct an in vitro cell model of COPD. Then, cell viability and apoptosis were detected by CCK-8 and flow cytometry. Meanwhile, the levels of IL-6, TNF-α, ROS, Fe2+, MDA, and GSH were measured by ELISA and the corresponding kits. Bioinformatics analysis was used to predict the m6A methylation modification sites on LCN2 mRNA. Besides, the methylation modification level of LCN2 was monitored by MeRIP. The binding of METTL3 and IGF2BP3 to LCN2 was verified by RIP. And the stability of LCN2 mRNA was analyzed by actinomycin D. The role of LCN2 in COPD in vivo model was verified by constructing an in vivo mouse model.
resultsSilencing LCN2 could effectively reduce CSE induced HMVECs injury and ferroptosis. METTL3 stabilized LCN2 expression through m6A methylation. IGF2BP3 could bind to LCN2 and stabilize its expression. METTL3 inhibitor STM2457 could restore CSE induced HMVEC injury and ferroptosis. Additionally, overexpression of LCN2 could also reverse the effect of METTL3 silencing on CSE-induced HMVEC injury. METTL3 inhibited the NRF2/SLC7A11/GPX4 pathway by stabilizing LCN2. Moreover, knockdown of LCN2 alleviated lung injury and inflammatory response in COPD mice and activate NRF2/SLC7A11/GPX4 signaling pathway.
conclusionThis study confirmed that METTL3/IGF2BP3 enhanced the stability of LCN2 and hindered the NRF2/SLC7A11/GPX4 pathway through m6A methylation modification, thereby aggravating the progression of COPD. It provides a new direction for the study of the mechanism of COPD, identifies key molecules such as METTL3 and IGF2BP3, and lays a foundation for the development of COPD treatment strategies targeting m6A modification or NRF2 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.